The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

Trial Profile

The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Cardiomyopathies; Coronary artery disease; Left ventricular dysfunction
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ERIC
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to discontinued.
    • 26 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 26 Jan 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top